Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic lupus erythematosus
•
Pediatric Rheumatology
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?
Related Questions
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
How do you explain a very high positive ds-DNA antibody by Elisa but negative by IFA?
Do you always pursue testing for NOD2 mutations when you are suspecting a diagnosis of Blau syndrome?
How do you guide patients who seek online information about their disease to ensure it is accurate, supports their understanding, and minimizes unnecessary anxiety?
How do you evaluate and manage patients with lupus who are having issues with decreased libido?
Would you start hydroxychloroquine (or another DMARD) in a mid-20s female patient with positive ANA, SSA, SSB, and dsDNA, whose only clinical manifestation is intermittent parotid gland swelling?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
How would you approach a patient with newly diagnosed lupus/lupus nephritis receiving cyclophosphamide (euro lupus protocol) with active hemolysis not responding to steroids or IVIG?
How should rheumatologists address the impact on patients who are initially diagnosed with SLE based on positive ANA, but later reclassified as having UCTD?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
